Group Gp Lp Column III Acquires 18,052 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 18,052 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were purchased at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the acquisition, the insider owned 1,016,658 shares in the company, valued at $19,926,496.80. The trade was a 1.81% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Friday, January 16th, Group Gp Lp Column III acquired 2,562 shares of Surrozen stock. The stock was purchased at an average cost of $20.00 per share, for a total transaction of $51,240.00.
• On Thursday, January 15th, Group Gp Lp Column III bought 11,893 shares of Surrozen stock. The shares were purchased at an average cost of $19.89 per share, with a total value of $236,551.77.
• On Wednesday, January 14th, Group Gp Lp Column III bought 5,523 shares of Surrozen stock. The stock was acquired at an average cost of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 13th, Group Gp Lp Column III purchased 12,470 shares of Surrozen stock. The shares were acquired at an average cost of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III acquired 15,100 shares of Surrozen stock. The stock was acquired at an average price of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III acquired 30,884 shares of Surrozen stock. The stock was acquired at an average cost of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III bought 5,266 shares of Surrozen stock. The shares were acquired at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III bought 315,457 shares of Surrozen stock. The shares were acquired at an average cost of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Trading Up 6.6%

NASDAQ SRZN opened at $19.17 on Thursday. The company has a market cap of $164.29 million, a price-to-earnings ratio of -0.86 and a beta of 0.58. The company has a 50 day moving average of $19.11 and a 200-day moving average of $14.17. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $24.94.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The company had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. On average, equities research analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Surrozen News Roundup

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Director Tim Kutzkey completed several open‑market buys on Jan 6, 13, 14, 15, 16 and 20 totaling tens of thousands of shares (~$641k reported across the most recent three purchases) and now directly owns ~1.02M shares — insider accumulation is often read as a bullish confidence vote. Surrozen (NASDAQ:SRZN) Director Purchases $51,240.00 in Stock
• Positive Sentiment: Major shareholder Group GP LP Column III mirrored the insider purchases (Jan 15, 16 and 20), increasing its stake by ~1.2–1.8% per disclosed tranche to ~1.02M shares — coordinated buying by a large holder reinforces the positive insider signal. Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Acquires 2,562 Shares
• Neutral Sentiment: The disclosures are routine SEC beneficial‑ownership filings that document the trades and updated holdings; they do not indicate corporate actions (e.g., buybacks or financings) by Surrozen itself. SEC filing — Kutzkey purchases
• Negative Sentiment: Company fundamentals remain weak: Surrozen reported a steep Q3 EPS miss (reported -$3.61 vs -$1.17 expected) and minimal revenue, leaving substantial operating losses that could cap the stock’s upside unless clinical or commercial progress materially improves. MarketBeat — SRZN profile

Hedge Funds Weigh In On Surrozen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Braidwell LP bought a new stake in shares of Surrozen during the second quarter worth $1,252,000. Stempoint Capital LP boosted its holdings in shares of Surrozen by 185.1% during the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after acquiring an additional 445,713 shares in the last quarter. Stonepine Capital Management LLC grew its position in Surrozen by 7.1% during the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after acquiring an additional 20,247 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Surrozen by 21.7% in the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock valued at $3,433,000 after buying an additional 47,468 shares during the period. Finally, Acuta Capital Partners LLC increased its position in Surrozen by 5.0% in the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after acquiring an additional 8,415 shares during the period. Institutional investors own 66.57% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on SRZN. Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Finally, Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Surrozen presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.